(Q43049458)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

author name string

G Fattovich

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

I Zagni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

E Minola

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

P Fabris

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

S Boccia

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M Giusti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

G Abbati

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M Felder

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

P Rovere

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

A Redaelli

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

A Tonon

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

R Montanari

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

C Paternoster

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M Distasi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

E Castagnetti

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

G Tositti

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

C Rizzo

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

S Suppressa

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M Pantalena

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

L Lomonaco

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

C Scattolini

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

A Tagger

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 March 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

1 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

111-117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Combination of interferon induction therapy and ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Favourable and disappointing lessons from viral kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00409.X

10.1046/J.1365-2893.2003.00409.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12614467%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference